A new class of non-opioid drugs treats pain by blocking signals before they reach the brain, reducing the risk of addiction.

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...

The FDA has approved Journavx 50 mg oral tablets for the treatment of moderate to severe acute pain in adults, according to a ...

The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in more than 20 years.

The US Food and Drug Administration has approved a new, nonopioid pain medication for treating moderate to severe acute pain.

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...

The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and ...

Suzetrigine selectively inhibits the NaV1.8 pain-signaling pathway in the peripheral nervous system and provides effective ...

( The Hill) – The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first ...

The U.S. Food and Drug Administration (FDA) on Thursday approved a new type of prescription pain medication for adults to ...

Women's pain is often misdiagnosed or ignored. But what's being done about it? We asked women and MDs to weigh in on.